Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS)

Table 2 Comparison of the changes in individual CRISS variables and final CRISS outcome at 1 year between the exposed and unexposed groups

	Exposed, n = 47	Unexposed, n = 254	p
Change in CRISS variables (mean ± SD)
mRSS	− 1.1 ± 6.4	− 0.3 ± 6.3	0.28
FVC %predicted	− 1.3 ± 11.1	− 0.4 ± 7.9	0.66
HAQ	− 0.1 ± 0.5	0 ± 0.3	0.56
PTGA disease severity	− 0.4 ± 1.8	0 ± 1.6	0.03
PGA disease severity	0.1 ± 2.1	− 0.1 ± 2.0	0.79
CRISS outcomen(%)
Automatically not improved CRISS (step 1)*	5 (10.6%)	8 (3.1%)	0.02
Improved CRISS at 1 year	11 (23.4%)	30 (11.8%)	0.03
Improvement among subjects with calculated CRISS (step 2)n(%)^#	n = 42	n = 246
Improved mRSS ≥ 5	13 (31.0%)	50 (20.3%)	0.12
Improved FVC %predicted ≥ 5	11 (26.2%)	56 (22.8%)	0.63
Improved HAQ ≥ 0.14	13 (31.0%)	53 (21.5%)	0.18
Improved PTGA disease severity ≥ 2	18 (42.9%)	65 (26.4%)	0.03
Improved PGA disease severity ≥ 2	11 (26.2%)	85 (34.6%)	0.28

mRSS modified Rodnan skin score, FVC% percent of predicted forced vital capacity, HAQ Health Assessment Questionnaire, PTGA patient global assessment, PGA physician global assessment, CRISS composite response index in diffuse systemic sclerosis
*Of those considered not improved, these are patients with significant new or worsening organ involvement who were assigned an automatic CRISS score of 0 without the need for formulaic calculation of CRISS score
^#Cutoffs represent the absolute difference in measures after 1 year towards an improved score

ISSN: 1478-6362